# Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

> **NCT02405221** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 15 (actual)

## Conditions studied

- HPV16 Associated Cervical Cancer

## Interventions

- **BIOLOGICAL:** TA-CIN (arm)
- **BIOLOGICAL:** TA-CIN (thigh)

## Key facts

- **NCT ID:** NCT02405221
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405221, "Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02405221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*